SNP-610 is under clinical development by Sinew Pharma and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SNP-610 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SNP-610 overview
SNP-610 is under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). It is administered through the oral route as a tablet. The drug candidate acts by targeting diacylglycerol O-acyltransferase 1 (DGAT1), hormone-sensitive lipase and CYP2E1 enzymes. It is a first-in-class drug candidate.
Sinew Pharma overview
Sinew Pharma is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of liver disease treatment drugs and pain medication. The Company’s main products include f
For a complete picture of SNP-610’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
